Close menu




Biotech

Photo credits: pixabay.com

Commented by André Will-Laudien on July 25th, 2025 | 07:05 CEST

Biotech turns to gold: Who is swallowing whom - or what? Evotec, BioNxt, Valneva, and Formycon are on the list!

  • Biotechnology
  • Biotech
  • Pharma

The biotech sector is closely monitoring central bank interest rates. At present, however, inflation still seems a little too high to expect significant cuts. Accordingly, the European Central Bank left its key interest rates unchanged yesterday. Investors are now looking to Wall Street for signals on where rates might head in the second half of the year. However, due to the sharp price increases on the Nasdaq and existing undervaluations, takeover rumors are starting to circulate - and could materialize at any time. BioNxt, Evotec, and Valneva are on our watchlist. Where do the opportunities lie for investors?

Read

Commented by Nico Popp on July 25th, 2025 | 07:00 CEST

Key technology in the fight against cancer? Merck & Co., Vidac Pharma, AstraZeneca

  • Biotechnology
  • Pharma
  • Cancer
  • Technology

Do you know what aerobic glycolysis is? No? Have you ever heard of the Warburg effect? Both terms describe the same phenomenon: cancer cells utilize glucose to produce lactate, even in the presence of oxygen and fully functional mitochondria. This is what distinguishes cancer cells from healthy cells. Current research suggests that targeted interventions in the Warburg effect could be suitable for killing cancer cells or making them more receptive to other therapies. Companies around the world are pushing forward research into this effect – the goal is nothing less than curing cancer. We present some of the companies and analyze whether their stocks could be good investments.

Read

Commented by Fabian Lorenz on July 24th, 2025 | 07:20 CEST

AI stocks: Buy SAP now? BioNTech surprises! NetraMark beats ChatGPT!

  • Biotechnology
  • Biotech
  • AI

SAP shares performed poorly yesterday. However, the software company is running smoothly and making progress in expanding its AI and cloud business. Is now a good time to get in? Analysts see around 50% upside potential for NetraMark shares. The AI specialist supports Big Pharma in efficient drug development – a billion-dollar market. Now NetraAI has even beaten ChatGPT and DeepSeek! BioNTech is also betting on artificial intelligence. However, the Mainz-based company is currently only making headlines with a change in personnel, but this could change on August 4. Will there be new impetus soon?

Read

Commented by Fabian Lorenz on July 23rd, 2025 | 07:10 CEST

TAKEOVER SPECULATION! Barrick Mining, Evotec, Desert Gold

  • Mining
  • Gold
  • Biotechnology
  • Takeover

Just like the high prices, takeover speculation in the gold sector is also continuing. Desert Gold is repeatedly mentioned as a candidate. With its exciting acquisition in West Africa, the explorer has diversified and made itself even more attractive to a large corporation. Perhaps Barrick? The heavyweight is currently focusing on its ore mines and selling smaller projects. It could then expand again in the gold sector, and Desert certainly fits in regionally. In the biotech sector, Evotec has long been rumored as a takeover candidate. Following the latest revenue warning, this is likely the only hope for investors to achieve short-term returns. Or was the price slide exaggerated?

Read

Commented by Stefan Feulner on July 22nd, 2025 | 07:15 CEST

Netflix, NetraMark, Novo Nordisk – Positive signals

  • Biotechnology
  • Biotech
  • Pharma
  • Streaming

So much for the old saying: "Sell in May and go away". If investors had followed this well-known stock market adage, they would have missed out on some significant gains in 2025. Instead, the world's most important indices, such as the Dow Jones, S&P 500, and NASDAQ, are close to their historic highs. And there is no sign of a summer slump, as the first-half earnings season kicked off last week. Despite already high valuations, further price gains could follow due to the positive market sentiment.

Read

Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST

Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio

  • AI
  • Biotechnology
  • Biotech
  • Pharma

In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.

Read

Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST

Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution

  • Biotechnology
  • Biotech
  • Healthcare
  • healthtech

The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.

Read

Commented by André Will-Laudien on July 15th, 2025 | 07:30 CEST

Bitcoin and exchanges in IPO and hysteria mode! AI millions from NetraMark Holdings, Clara Technologies, BitMine, and D-Wave

  • Biotechnology
  • Biotech
  • AI
  • Innovations
  • computing
  • Bitcoin

The recent IPOs on the NASDAQ show just how quickly innovations can materialize. No sooner are they listed than they skyrocket, because what is new must be good! Or is it? From a distance, stock market professionals are beginning to wonder whether everything is still above board. The crypto company BitMine, for example, gained 2,000% within two weeks, only to lose a third of its value after announcing a USD 2 billion capital increase. Clara Technologies debuted on the stock market in January with prices around CAD 0.50. By the end of last week, the share price had exploded to around CAD 16, a 32-fold increase. Our advice: Investors should examine business models very carefully before entering the ring. AI newcomer NetraMark is fully embracing the trends toward digitization and increased accuracy through the use of AI in the clinical trial sector. Where do the opportunities and risks lie for agile investors?

Read

Commented by André Will-Laudien on July 14th, 2025 | 07:25 CEST

DAX correction! Biotech in takeover mode! BioNTech, CureVac, Pfizer, Vidac Pharma, and Kraft Heinz in focus

  • Biotechnology
  • Biotech
  • Pharma

The stock markets are in top form: both the DAX and the NASDAQ 100 have flexed their muscles in recent days. Prices are being driven primarily by the continued strength of technology stocks and growing hopes for stable global economic growth, despite Donald Trump's tariff madness. At the same time, a growing takeover fever in the biotechnology sector is providing additional momentum. In the field of cancer research in particular, companies such as BioNTech, Moderna, and other specialized mRNA players such as CureVac are increasingly becoming the focus of strategic investors. The fight against cancer is increasingly becoming one of the key drivers for new partnerships and market consolidation. Speculation about possible mergers and billion-dollar acquisitions is currently on the rise again. This opens up an exciting environment for investors, offering opportunities for above-average returns. We identify the trigger points.

Read

Commented by Fabian Lorenz on July 11th, 2025 | 07:20 CEST

Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!

  • Biotechnology
  • Biotech
  • Pharma

The takeover merry-go-round is spinning faster again in the biotech sector. The latest example is Merck's acquisition of Verona Pharma. The US group is paying USD 10 billion for the deal. BioNxt Solutions would be significantly cheaper to acquire at present. The Company aims to make it easier to take medication with melt films, skin patches, and tablets. In addition, it has now announced an exciting platform. The goal is to develop smarter chemotherapy, which, in turn, could create a billion-dollar market. And what are BioNTech and Evotec doing? Things have quieted down a bit at the German biotech leader following its billion-dollar deal with Bristol-Myers Squibb. However, analysts recommend buying the stock. Evotec, on the other hand, is languishing at around EUR 7. Can the quarterly figures provide new impetus for the struggling stock?

Read